Trials Sponsors Conditions Drugs Pricing

Conditions

Acne Vulgaris

Outcome Measures

Primary Outcomes (1)

Global Acne Grading System (GAGS) Score
Acne Vulgaris Severity assesment by GAGS score
12 weeks

Study Arms (2)

Group A

EXPERIMENTAL

Metformin 500 mg twice daily along with topical retinoids for 12 weeks

Drug: Metformin and doxycycline

Group B

ACTIVE COMPARATOR

Doxycycline 100 mg twice daily along with topical retinoids for 12 weeks

Drug: Metformin and doxycycline

Interventions

Metformin and doxycyclineDrug

Metformin 500 mg tablet twice daily

Group AGroup B

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
Metformin and doxycycline
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Newly diagnosed moderate and severe AV patients diagnosed by a dermatologist

You may not qualify if:

Sponsors & Collaborators

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Otherlead

Study Sites (1)

BSMMU

Dhaka, Bangladesh

RECRUITING

registrarCONTACT8512550 registrar@bsmmu.edu.bd

MeSH Terms

Conditions

Acne Vulgaris

Interventions

MetforminDoxycycline

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic ChemicalsTetracyclinesNaphthacenes

Central Study Contacts

Muhammad Marnush, MBBS

CONTACT

88001714558447 marnushm@gmail.com

Study Design

Study Type: interventional
Phase: phase 2
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

January 30, 2024

First Posted

February 9, 2024

Study Start

March 5, 2023

Actual (reported)

Primary Completion

March 2024

Estimated (date passed)

Comparative Study of Metformin Versus Doxycycline in Moderate to Severe Adult Acne Vulgaris Patients.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Group A

Group B

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Group A

Group B

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

Data Sharing

Source record

Locations